       Document 0194
 DOCN  M9610194
 TI    Notes on the use of fluvoxamine as treatment of depression in
       HIV-1-infected subjects.
 DT    9601
 AU    Grassi B; Gambini O; Scarone S; Department of Biomedical and
       Technological Sciences, University; of Milan Medical School, Italy.
 SO    Pharmacopsychiatry. 1995 May;28(3):93-4. Unique Identifier : AIDSLINE
       MED/96031739
 AB    Fluvoxamine belongs to the class of selective serotonin reuptake
       inhibitors (SSRIs) which have recently gained large popularity as
       antidepressant agents essentially because they lack the most troublesome
       adverse effects of older antidepressants (i.e. tricyclic
       antidepressants) such as anticholinergic effects and cardiotoxicity.
       Recent studies in the literature suggest that HIV-1 infected subjects
       are affected by depressive episodes with a relatively high frequency,
       often requiring an antidepressant treatment. Due to its favorable
       adverse effects profile, we used fluvoxamine as first line treatment for
       sixteen depressed HIV-1 infected subjects. They were administered the
       drug at a daily dosage of 100 mg in the evening. Fluvoxamine provided a
       good clinical efficacy for six of these patients, whereas the other ten
       had to discontinue the drug because of the presence of severe adverse
       effects such as acute total insomnia, gastro-intestinal disturbances
       together with anorexia, aggressive and impulsive behavior and excessive
       sedation. The observed fluvoxamine side-effects are not typical or
       specific for this particular patient group since they are also described
       in seronegative subjects taking fluvoxamine; however, our findings seem
       to indicate that they become more frequent and more severe when the drug
       is administered to HIV-1 infected patients.
 DE    Adult  Antidepressive Agents, Second-Generation/ADVERSE EFFECTS/
       *THERAPEUTIC USE  Depressive Disorder/*DRUG THERAPY/ETIOLOGY/PSYCHOLOGY
       Female  Fluvoxamine/ADVERSE EFFECTS/*THERAPEUTIC USE  Human  HIV
       Infections/COMPLICATIONS/*PSYCHOLOGY  *HIV-1  Male  Psychiatric Status
       Rating Scales  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

